Cryoport, Inc. (CYRX) director Ramkumar Mandalam recently executed a sale of 23,214 shares of the company's common stock, realizing a total value of $358,452. The transactions were finalized on June 8, 2026, with shares sold at a weighted average price of $15.4412. According to the filing, these shares were sold in multiple transactions at prices ranging from $15.40 to $15.48, inclusive. Following these sales, Mr. Mandalam directly holds 67,894 shares of Cryoport common stock.
This sale comes as Cryoport stock trades near its 52-week high of $16.73, with shares delivering a remarkable 122% return over the past year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value. Investors can access comprehensive analysis through the company's detailed Pro Research Report, available for CYRX and 1,400+ other US equities.
Earlier, on June 5, 2026, Mr. Mandalam acquired 10,350 shares of common stock. These shares represent a grant of restricted stock rights that will vest in full on June 5, 2027, and automatically convert to shares of common stock on a one-for-one basis upon vesting.
Also on June 5, 2026, Mr. Mandalam was granted options to purchase 16,077 shares of Cryoport common stock. These options have an exercise price of $15.70 per share and are set to expire on June 5, 2033. The options will vest in monthly increments of 1/12th of the total, beginning July 5, 2026, for twelve months.
In other recent news, CryoPort reported its first-quarter fiscal 2026 earnings, revealing a larger-than-expected loss per share, with EPS at -$0.25 compared to the anticipated -$0.22. However, the company exceeded revenue forecasts, with total revenue reaching $47.8 million, surpassing the consensus estimate of $44.87 million. This performance led CryoPort to raise its revenue guidance for fiscal 2026. Analysts have responded positively to these developments, with Needham increasing its price target for CryoPort to $15, citing the revenue beat as a key factor. Similarly, BTIG raised its price target to $17, acknowledging the strong revenue results and adjusted EBITDA figures that outperformed expectations. KeyBanc also adjusted its price target to $17, highlighting improved revenue visibility and quality. These recent developments reflect a broad-based strength across CryoPort's business.
Cryoport IncFollowAnalyze CYRXIncluded in our AI-picked strategies·Review strategies15.48▼-0.22(-1.40%)Closed·15:59:59·USD15.68▲+0.20(+1.32%)After Hours·19:08:011D1W1M6M1Y5YMaxCreated with Highcharts 11.4.814:0015:0016:0017:0018:0019:0015.2515.515.75Analyze CYRXThis article was generated with the support of AI and reviewed by an editor. For more information see our T&C.See the trade on CYRX, but can't pull the trigger?Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.Try Chart Analysis for CYRX